← ANALYST RATINGS · TIPRANKS
Immatics (IMTX): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $17.16, the highest $25.00, the lowest $11.80. The average is +155.0% from the last price of $6.73.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.00 → $6.50−7.1% | Hold | −3.4% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $6.50−13.3% | Hold | −3.4% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $6.50−13.3% | Hold | −3.4% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.00 → $6.50−7.1% | Sell | −3.4% | Downgrade | 14.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $6.50−13.3% | Hold | −3.4% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $6.50−13.3% | Hold | −3.4% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $15.00 | Buy | +122.9% | Initiated | 13.10.26on TipRanks 16:30 | +3.6%next day +1.7% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $18.00 → $17.00−5.6% | Buy | +152.6% | Assigned | 25.08.26on TipRanks 13:40 | +6.0%next day +2.0% · 5 days +2.6% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $25.00 | Buy | +271.5% | Reiterated | 20.08.26on TipRanks 09:30 | −6.7%next day +4.0% · 5 days +8.4% | ↗ |
| Nicholas Lorusso★★★★★★★★★★#2971 · hits 56% · avg +39.7% | TD Cowen | — | Buy | — | Reiterated | 18.08.26on TipRanks Aug 19 09:40 | −1.1%next day +1.5% · 5 days +1.9% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $17.00 | Buy | +152.6% | Reiterated | 18.08.26on TipRanks Aug 19 04:50 | −1.1%next day +1.5% · 5 days +1.9% | ↗ |
| Rajan Sharma★★★★★★★★★★#5820 · hits 52% · avg +1.9% | Goldman Sachs | $12.20 → $11.80−3.3% | Buy | +75.3% | Reiterated | 18.08.26on TipRanks Aug 19 01:10 | −1.1%next day +1.5% · 5 days +1.9% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $25.00 | Buy | +271.5% | Reiterated | 19.05.26on TipRanks 16:30 | +3.8%next day −1.6% · 5 days +0.2% | ↗ |
| Paul Jeng★★★★★★★★★★#9457 · hits 52% · avg −1.9% | Guggenheim | $19.00 | Buy | +182.3% | Reiterated | 12.05.26on TipRanks May 13 07:15 | −1.1%next day −5.8% · 5 days −5.5% | ↗ |
| Jonathan Chang★★★★★★★★★★#2398 · hits 37% · avg +7.3% | Leerink Partners | $17.00 | Buy | +152.6% | Reiterated | 06.03.26on TipRanks 09:30 | −1.5%next day +0.5% · 5 days −4.8% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $18.00 | Buy | +167.5% | Reiterated | 11.12.25on TipRanks 13:10 | −0.4%next day +1.1% · 5 days −2.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Immatics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 13.10.26: target $17.16 at a price of $7.21 (+138.0%); now: $17.16 at $6.73 (+155.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 5 | 4 | 3 | 3 | 4 |
| Buy | 6 | 7 | 6 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.51 (from $-0.62 to $-0.43). Last quarter: $-0.52.
Sales
Next quarter’s sales estimate — $12M (from $7M to $16M). Last quarter: $11M.
Best top-analyst consensus in the sector · Healthcare
About Immatics
- CEO: Harpreet Singh
- Employees: 704
- Paul-Ehrlich-Strasse 15, Tübingen, BW, 72076, DE
- www.immatics.com
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Data from the stock’s TipRanks forecast page, read 113 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗